Hopp til innhold
NHI.no
Annonse
Informasjon

Hvite flekker på huden, vitiligo

Vitiligo er en tilstand med pigmentfrie, hvite, flekker i huden. Det finnes ingen god behandling mot tilstanden. Behandlingen som kan brukes, er langvarig, og resultatene usikre.

Bildequiz, uke 42.jpg
Vitiligo (bildet): Tilstanden rammer omtrent en til to prosent av befolkningen.

Sist oppdatert:

13. mars 2019

Innhold i artikkelen

Hva er vitiligo?

Annonse

Vi regner med at én til to prosent av befolkningen har vitiligo, det vil si cirka 50.000 personer i Norge. Tilstanden er like hyppig blant kvinner som menn. Vanligste debutalder er 10-30 år, men tilstanden kan debutere i alle aldersgrupper. Hos omtrent 30 prosent finnes familiær opphopning av tilfeller.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Vitiligo . Referanselisten for dette dokumentet vises nedenfor

  1. Sitek JC. Vitiligo - tap av pigment i huden. Tidsskr Nor Lægeforen 2006; 126: 2370-2. PubMed
  2. Roncone K. Vitiligo. Medscape, last updated Aug 10, 2018.
  3. Huang CL, Nordlund JJ, Boissy R. Vitiligo: a manifestation of apoptosis? Am J Clin Dermatol 2002; 3: 301-8. PubMed
  4. Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001; 2: 167-81. PubMed
  5. Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?. Exp Dermatol. 2008 Feb. 17(2):139-40; discussion 141-60.
  6. Passerou T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmunology 2005; 25: 63-8. PubMed
  7. Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993; 129: 994. PubMed
  8. Harris JE, Rashighi M. Vitiligo. BMJ Best Practice, last updated July 2018.
  9. Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015 Feb 24;2:CD003263. The Cochrane Library
  10. Taieb A, Alomar A, Böhm M, et al; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168:5-19. PubMed
  11. Gargoom AM, Duweb GA, Elzorghany AH, Benghazil M, Bugrein O. Calcipotriol in the treatment of childhood vitiligo. Ped Dermatol 2004; 21: 495-8. PubMed
  12. Travis LB, Silverberg NB. Calcipotriene and corticosteroid combination therapy for vitiligo. Pediatr Dermatol 2004; 21 (4): 495-8.
  13. Boone B, Ongenae K, Van Geel N, et al. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol. 2007;17:55-61. PubMed
  14. Silverberg NB, Lin P, Travis L et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: A review of 57 cases. J Am Acad Dermatol 2004; 51: 760-6. PubMed
  15. Lee JH, Kwon HS, Jung HM et al. Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol 2019. pmid:31141108 PubMed
  16. Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat. 2009. 20(1):14-8.
  17. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J AM Acad Dermatol 2000; 42: 245-53. PubMed
  18. Natta R, Somsak T, Wisuttida T, Laor L. Narrowband ultraviolet b radiation therapy for recalcitrant vitiligo in Asians. J Am Acad Dermatol 2003; 49: 473-6. PubMed
  19. Stern RS, Lange R. Nonmelanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91: 120-4. PubMed
  20. Hamzavi I, Jain H, McLean D et al. Parametric modelling of narrowband UVB phototherapy for vitiligo using a novel quantitative tool: the vitiligo area scoring index. Arch Dermatol 2004; 140: 677-83. PubMed
  21. Olsson MJ, Juhlin L. Long-term follow-up of leucoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension. Br J Dermatol 2002; 147: 893-904. PubMed
  22. Razmi TM, Kumar R, Rani Sc, et al. Combination of Follicular and Epidermal Cell Suspension as a Novel Surgical Approach in Difficult-to-Treat Vitiligo: A Randomized Clinical Trial. JAMA Dermatol 2018. pmid:29387874 PubMed
Annonse
Annonse